SARS-CoV-2 infection in high-risk children following tixagevimab–cilgavimab (Evusheld) pre-exposure prophylaxis: a single-center observational study

From 8 December 2021 to 26 January 2023, tixagevimab–cilgavimab (T-C) was authorized for pre-exposure prophylaxis of COVID-19. During this period, we used a multidisciplinary team to communicate, screen, approach, and administer T-C to eligible patients. Twenty-seven patients were eligible. Of these...

Descripción completa

Detalles Bibliográficos
Autores principales: Hijano, Diego R., Ferrolino, Jose A., Swift, Elizabeth G., Michaels, Carolyn A., Max, Anita, Hayden, Randall T., Wolf, Joshua, Dallas, Ronald H., Greene, William L., Richardson, Julie L., Hakim, Hana, Morton, Ted H., Cross, Shane J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10436088/
https://www.ncbi.nlm.nih.gov/pubmed/37601666
http://dx.doi.org/10.3389/fonc.2023.1229655

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10436088/
https://www.ncbi.nlm.nih.gov/pubmed/37601666
http://dx.doi.org/10.3389/fonc.2023.1229655

Ejemplares similares